✨ Free AI Report
Arvinas, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Arvinas, Inc.
Company Research

Arvinas, Inc.: Business Overview, Financials & Competitive Analysis

Arvinas, Inc. scores 6/10 on the AskCyborg Cyborg Score (Solid). Clinical-stage biotech with innovative PROTAC platform approaching regulatory catalysts, but elevated execution risk and cash burn typical of pre-commercial stage. Vepdegestrant received FDA Fast Track designation with a PDUFA action date of June 5, 2026. The company has strong cash position and differentiated technology, but faces financial losses and recent.

What is Arvinas, Inc.'s industry? Arvinas, Inc. (arvinas.com) operates in Biotechnology - Targeted Protein Degradation. AskCyborg classifies Arvinas, Inc. under Biotechnology - Targeted Protein Degradation in its company registry.

Arvinas is a clinical-stage biotechnology company pioneering targeted protein degradation therapies through its PROTAC platform, designed to degrade disease-causing proteins using the body's natural protein disposal s...

6/ 10Solid

Cyborg Score thesis

Clinical-stage biotech with innovative PROTAC platform approaching regulatory catalysts, but elevated execution risk and cash...

Read the full analyst-debate transcript →
Industry Biotechnology - Targeted Protein Degradation
2 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Arvinas, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Arvinas, Inc.

AskCyborg analysts argue the bull and bear cases for Arvinas, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Arvinas, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Arvinas, Inc. Overview

Pro stress-test →

Arvinas is a clinical-stage biotechnology company pioneering targeted protein degradation therapies through its PROTAC platform, designed to degrade disease-causing proteins using the body's natural protein disposal system. The company is advancing a robust pipeline with multiple clinical programs targeting oncology, neurodegenerative diseases, and other serious conditions.

Strategic Profile

Pro stress-test →

Arvinas is progressing multiple investigational drugs through clinical development including ARV-102 for neurodegenerative disorders, ARV-806 for KRAS G12D mutations, ARV-393 for non-Hodgkin Lymphoma, and vepdegestrant for ER+/HER2- breast cancer. The company has collaborations with Pfizer, Genentech, Roche, Carrick Therapeutics, and Bayer.

Competitive Landscape

Pro stress-test →

Arvinas operates in the targeted protein degradation space with differentiation through its PROTAC platform technology. Competitors include Relay Therapeutics ($1.36B market cap) and Nurix Therapeutics ($1.77B market cap), both also in biotechnology. Arvinas' focus on multiple oncology and neurology programs with major pharma partnerships differentiates it within the segment.

Industry Context

Arvinas, Inc. operates in Biotechnology - Targeted Protein Degradation.

Key facts

Founded: 2013 · Headquarters: New Haven, Connecticut · Revenue: $312.3M · Market cap: $820M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Arvinas, Inc..

  • CEO John Houston resigned February 12, 2026, with Randy Teel appointed as new president and CEO, bringing strategic experience to focus on clinical pipeline development.
  • Arvinas and Pfizer agreed to out-license vepdegestrant commercialization rights to a third party to maximize commercial potential.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Randy Teel appointed President and CEO, succeeding John Houston with focus on strategic pipeline acceleration
  • June 2026Vepdegestrant FDA PDUFA decision expected for ER+/HER2- breast cancer
  • +1 moreTrack every material event for Arvinas, Inc. as it happens. Explore monitoring →
Get alerted when Arvinas, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

RLAYClinical-stage biotech focusing on protein degradation→NRIXOncology-focused targeted protein degradation biotech→

Compare Arvinas, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Arvinas, Inc. operates in Biotechnology - Targeted Protein Degradation. See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - Targeted Protein Degradation research →
NEW · MCP server

Ask your AI assistant about Arvinas, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Arvinas, Inc. and its top competitor on Cyborg Score”
“What did Arvinas, Inc. do this quarter?”
“Is Arvinas, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Arvinas, Inc. do?+
Arvinas is a clinical-stage biotechnology company pioneering targeted protein degradation therapies through its PROTAC platform, designed to degrade disease-causing proteins using the body's natural protein disposal s...
What is Arvinas, Inc.'s Cyborg Score?+
Arvinas, Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Arvinas, Inc.'s main competitors?+
Named competitors include RLAY, NRIX. The full competitive landscape is in the AskCyborg report.
How can I get the full Arvinas, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Arvinas, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Arvinas, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biotechnology - Targeted Protein Degradation research

Companies in the same sector and named competitors, ranked by Cyborg Score.

6Arvinas, Inc.